BioSpace News Archive

Conference call and webcast (in English) tomorrow, March 16, 2021 at 2:00pm CET (1:00pm GMT/9:00am EDT) MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) reports results for the year ended December 31, 2020

Biohaven Pharmaceutical Holding Company Ltd., a commercial–stage biopharmaceutical company with a marketed drug for the acute treatment of migraine and a portfolio of innovative, late–stage product candidates targeting neurological diseases, including rare disorders, announced the pricing of its underwritten public offering of 2,686,409 of its common shares at a price to the public of $76.00 per share.

The Centre for Disease Control and Prevention has declared insufficient sleep a ‘public health problem’, with more than one-third of American adults not getting enough sleep on a regular basis.

BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases based on a portfolio built around gelsolin technology, announced today that it has completed enrollment for its Phase 2 study of hospitalized patients with severe COVID-19 pneumonia.

Mr. Dolban has been involved in new business development for over 25 years and is currently focusing his experience into resource-based sectors.

US-based biotech company VLP Therapeutics, Inc. announced that it has named Ms. Miwa Toyoda, formerly a venture capitalist specialized in pharma and biotech at JAFCO Group Co., Ltd., as chief business officer, effective March 15, in a bid to accelerate its vaccine research and development projects and expand the portfolio.

Tetra Bio-Pharma Inc., a biopharmaceutical pioneer in immunomodulator drug discovery and development announce that the Dronabinol Soft Gel capsules New Drug Submission file submitted to Health Canada on December 30, 2020 has completed the screening phase.

Med tech company Pelican Diagnostics, a Canary Global Inc. company has received CE Mark for a 25-second COVID-19 saliva test, delivering real-time results with 98% sensitivity and 100% specificity.

Increasing cases of cancer among infants to bolster the sales for pediatric neuroblastoma treatment market

When there is an imbalance between the production and absorption of cerebrospinal fluid, is known as hydrocephalus.